GMAB - J&J sets guidance below consensus as MedTech underperforms
2024-04-16 07:20:23 ET
Reporting its Q1 2024 results, Big Pharma’s earnings bellwether, Johnson & Johnson ( NYSE: JNJ ), revised its full-year outlook below consensus on Tuesday after sales from its MedTech division fell short of Street forecasts....
J&J sets guidance below consensus as MedTech underperforms